U-937 (ATCC® CRL-1593.2)

Organism: Homo sapiens, human  /  Tissue: Pleura/pleural effusion, lymphocyte, Myeloid  /  Disease: histiocytic lymphoma

Permits and Restrictions

View Permits View Restrictions

Organism Homo sapiens, human
Tissue Pleura/pleural effusion, lymphocyte, Myeloid
Product Format frozen
Morphology monocyte
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease histiocytic lymphoma
Age 37 years
Gender male
Ethnicity Caucasian
Applications
This cell line is suitable as a transfection host
Storage Conditions liquid nitrogen vapor phase
Images ATCC CRL-1593.2 Cell Micrograph
Derivation
The U-937 cell line was derived by Sundstrom and Nilsson in 1974 from malignant cells obtained from the pleural effusion of a patient with histiocytic lymphoma.
Clinical Data
37 years
Caucasian
male
The U-937 cell line was derived by Sundstrom and Nilsson in 1974 from malignant cells obtained from the pleural effusion of a patient with histiocytic lymphoma.
Receptor Expression
complement (C3)
Genes Expressed
lysozyme; beta-2-microglobulin (beta 2 microglobulin); tumor necrosis factor (TNF), also known as tumor necrosis factor alpha (TNF-alpha, TNF alpha), after stimulation with phorbol myristic acid (PMA)
Cellular Products
lysozyme; beta-2-microglobulin (beta 2 microglobulin); tumor necrosis factor (TNF), also known as tumor necrosis factor alpha (TNF-alpha, TNF alpha), after stimulation with phorbol myristic acid (PMA)
Comments
Studies since 1979 have shown that U-937 cells can be induced to terminal monocytic differentiation by supernatants from human mixed lymphocyte cultures,
The cells are negative for immunoglobulin production and Epstein-Barr virus expression.
The cells express the Fas antigen, and are sensitive to TNF and anti-Fas antibodies.
In 1994, PCR and cytogenetic analyses showed that a number of stocks of U-937 were contaminated with the human myeloid leukemia cell line, K-562.
In the earliest stocks available, the level of contamination was 0.6%.
Distribution was discontinued in March 1994, except if required for patent purposes.
Anyone who wishes to receive a sample of this original material should contact the Head of the ATCC Patent Depository.
A stock of CRL-1593 found to be free of K-562 was propagated continuously for 8 weeks and tested weekly by PCR.
Distribution and seed stocks give DNA profiles characteristic of U-937 only.
Such preparations are now offered as authentic U-937 (ATCC CRL-1593.2) and are believed to be free of second subpopulations.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
Subculturing
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 105 viable cells/mL. Corning® T-75 flasks (catalog #431464) are recommended for subculturing this product.
Interval: Maintain cell density between 1 X 105 and 2 X 106 viable cells/mL.
Medium Renewal: Add fresh medium every 3 to 4 days (depending on cell density)
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
STR Profile
Amelogenin: X
CSF1PO: 12
D13S317: 10,12
D16S539: 12
D5S818: 12
D7S820: 9,11
THO1: 6, 9.3
TPOX: 8,11
vWA: 14, 15
Name of Depositor H Koren
Year of Origin 1974
References

Ralph P, et al. Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J. Exp. Med. 143: 1528-1533, 1976. PubMed: 1083890

. Gene expression during normal and malignant differentiation. London: Academic Press; 1985.

. International symposium on new trends in human immunology and cancer immunotherapy. Paris: Doin Editeurs; 1980.

Koren HS, et al. In vitro activation of a human macrophage-like cell line. Nature 279: 328-331, 1979. PubMed: 450085

Gidlund M, et al. Natural killer cells kill tumour cells at a given stage of differentiation. Nature 292: 848-850, 1981. PubMed: 7266653

Olsson I, et al. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1 alpha,25-dihydroxycholecalciferol. Cancer Res. 43: 5862-5867, 1983. PubMed: 6315218

Morimoto H, et al. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res. 53: 2591-2596, 1993. PubMed: 7684321

Giovannangeli C, et al. Accessibility of nuclear DNA to triplex-forming oligonucleotides: The integrated HIV-1 provirus as a target. Proc. Natl. Acad. Sci. USA 94: 79-84, 1997. PubMed: 8990164

Brigino E, et al. Interleukin 10 is induced by recombinant HIV-1 Nef protein involving the calcium/calmodulin-dependent phosphodiesterase signal transduction pathway. Proc. Natl. Acad. Sci. USA 94: 3178-3182, 1997. PubMed: 9096366

Reid YA, et al. Cell Line Cross-contamination of U-937. J. Leukocyte Biol. 57: 804, 1995. PubMed: 7759961

Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer 17: 565-577, 1976. PubMed: 178611

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
Restrictions

The original U-937 cell line was established by Dr. K. Nilsson's laboratory in 1974 and he has requested the following: (1) In all papers reporting any use of this cell line or any derivatives thereof a direct reference should be made to Sundstrom and Nilsson (Int. J. Cancer 17: 565-577, 1976). (2) Any proposed commercial use of the cells should be negotiated with Professor Kenneth Nilsson, Rudbeck Laboratory, SE-751 85 Uppsala, Sweden. (3) No distribution of any of the cells or sublines derived therefrom should be made to third parties; (4) The cells should be used for non-clinical, non-commercial research only.

References

Ralph P, et al. Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J. Exp. Med. 143: 1528-1533, 1976. PubMed: 1083890

. Gene expression during normal and malignant differentiation. London: Academic Press; 1985.

. International symposium on new trends in human immunology and cancer immunotherapy. Paris: Doin Editeurs; 1980.

Koren HS, et al. In vitro activation of a human macrophage-like cell line. Nature 279: 328-331, 1979. PubMed: 450085

Gidlund M, et al. Natural killer cells kill tumour cells at a given stage of differentiation. Nature 292: 848-850, 1981. PubMed: 7266653

Olsson I, et al. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1 alpha,25-dihydroxycholecalciferol. Cancer Res. 43: 5862-5867, 1983. PubMed: 6315218

Morimoto H, et al. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res. 53: 2591-2596, 1993. PubMed: 7684321

Giovannangeli C, et al. Accessibility of nuclear DNA to triplex-forming oligonucleotides: The integrated HIV-1 provirus as a target. Proc. Natl. Acad. Sci. USA 94: 79-84, 1997. PubMed: 8990164

Brigino E, et al. Interleukin 10 is induced by recombinant HIV-1 Nef protein involving the calcium/calmodulin-dependent phosphodiesterase signal transduction pathway. Proc. Natl. Acad. Sci. USA 94: 3178-3182, 1997. PubMed: 9096366

Reid YA, et al. Cell Line Cross-contamination of U-937. J. Leukocyte Biol. 57: 804, 1995. PubMed: 7759961

Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer 17: 565-577, 1976. PubMed: 178611